drugset / Trial / NCT03275701
Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC
NaSingle-groupOpen-labelTreatment
Summary
Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching from EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)
Timeline
- Start
- 2016-07
- Primary completion
- 2019-10
- Completion
- 2019-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABC | Unknown | — | — |
| Subject | DTG | Unknown | — | — |
| Subject | Lamivudine | Other / unclassified | — | — |